Autoinflammatory & rare systemic diseases
Potential stratification of TAFRO syndrome by anti-SS-A antibodies status and therapeutic response to rituximab
Authors' conclusion
TAFRO syndrome shows clinical heterogeneity and anti-SS-A antibody status may represent one potential factor associated with treatment response.
Study context
- Population
- Published cases of TAFRO syndrome, PubMed/MEDLINE, January 1977 to October 2024
- Participants
- 212 published cases
- Comparison
- Anti-SS-A antibody-positive vs antibody-negative TAFRO syndrome
- Anti-SS-A positiven = 37
- Outcome
- Response to rituximab (RTX) or TCZ by anti-SS-A antibody status
Methodological detailsretrospective analysis, literature review (PubMed/MEDLINE, January 1977 to October 2024)
- Retrospective analysis
- Literature review (PubMed/MEDLINE, January 1977 to October 2024)
Pooled result
As reported in the abstract
Response to RTX
P = 0.011
Further pooled results
| Outcome | P value |
|---|---|
| Serum IgG levelsSignificantly higher in anti-SS-A positive | P = 0.020 |
Response to tocilizumab (TCZ)
- Therapeutic response to TCZ not affected by anti-SS-A antibody status
Concomitant autoimmune diseases
- Cases with concomitant autoimmune diseases (Sjögren's disease (SjD) most common)
- 27
- Anti-SS-A positive cases fulfilling SjD classification criteria
- 12
Original publication
Potential stratification of TAFRO syndrome by anti-SS-A antibodies status and therapeutic response to rituximab. RMD Open. Published 21 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →